Related Experiment Video
Updated: Dec 13, 2025

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
Published on: October 28, 2020
Extracellular Superoxide Dismutase Is Associated With Left Ventricular Geometry and Heart Failure in Patients With
Xiuwen Li1,2, Yingying Lin1,2, Shaohua Wang3
1Guangdong Provincial Key Laboratory of Food, Nutrition and Health Guangzhou Guangdong Province China.
Insights
Serum Extracellular Superoxide Dismutase (Ec-SOD) activity decreases with abnormal left ventricular geometry and heart failure in cardiovascular disease patients. Lower Ec-SOD levels are linked to increased odds of developing heart failure, suggesting a protective role.
Area of Science:
- Cardiology
- Biochemistry
- Pathophysiology
Background:
- Extracellular superoxide dismutase (Ec-SOD) is a key antioxidant enzyme.
- The association between Ec-SOD, left ventricular (LV) geometry, and heart failure (HF) in cardiovascular disease (CVD) patients remains unclear.
Purpose of the Study:
- To investigate the relationship between serum Ec-SOD activity and LV geometry patterns.
- To assess the association of serum Ec-SOD activity with the presence of HF in CVD patients.
Main Methods:
- Cross-sectional study of 1047 CVD patients.
- Standard echocardiography for LV geometry assessment.
- Measurement of serum Ec-SOD activity.
Main Results:
- Serum Ec-SOD activity showed a significant decreasing trend from normal geometry to abnormal LV geometry with HF.
- Lower Ec-SOD levels were independently associated with increased odds of concentric and eccentric hypertrophy with and without HF.
- Each 10 U/mL increase in Ec-SOD activity reduced the odds of HF by 16.5% to 40.4% depending on geometry.
Conclusions:
- Serum Ec-SOD activity is independently associated with abnormal LV geometry and HF in CVD patients.
- Ec-SOD may play a protective role in preventing LV structural remodeling and the development of HF.
Abstract:
Background Extracellular superoxide dismutase (Ec-SOD) is a major scavenger of reactive oxygen species. However, its relationships with abnormal left ventricular (LV) geometry patterns and heart failure (HF) are still unknown in patients with cardiovascular disease. Methods and Results A cross-sectional study was carried out to evaluate the association of serum Ec-SOD activity with LV geometry, as well as HF in 1047 patients with cardiovascular disease. All participants underwent standard echocardiography examination and measurement of serum Ec-SOD activity. Overall, we found a significantly decreased trend of serum Ec-SOD activity from subjects with normal geometry (147.96±15.94 U/mL), subjects with abnormal LV geometry without HF (140.19±20.12 U/mL), and subjects with abnormal LV geometry and overt HF (129.32±17.92 U/mL) after adjustment for potential confounders (P for trend <0.001). The downward trends remained significant in the concentric hypertrophy and eccentric hypertrophy groups after stratification by different LV geometry patterns. Multinomial logistic regression analysis showed that each 10 U/mL increase in serum Ec-SOD activity was associated with a 16.5% decrease in the odds of concentric remodeling without HF (odds ratio [OR], 0.835; 95% CI, 0.736-0.948), a 40.4% decrease in the odds of concentric hypertrophy with HF (OR, 0.596; 95% CI, 0.486-0.730), a 16.1% decrease in the odds of eccentric hypertrophy without HF (OR, 0.839; 95% CI, 0.729-0.965) and a 34.0% decrease in the odds of eccentric hypertrophy with HF (OR, 0.660; 95% CI, 0.565-0.772). Conclusions Serum Ec-SOD activity was independently associated with abnormal LV geometry patterns with and without overt HF. Our results indicate that Ec-SOD might be a potential link between LV structure remodeling and the development of subsequent HF in patients with cardiovascular disease. Registration URL: https://www.clinicaltrials.gov; Unique identifier NCT03351907.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Cardiomyopathy V: Interprofessional Care
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation

